# Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

> **NCT03184090** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Endocrine therapy (non IMP)

## Key facts

- **NCT ID:** NCT03184090
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2020-10-27
- **Final completion:** 2020-10-27
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184090, "Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03184090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*